All Outputs (2)

A Hybrid Evolutionary Strategy to Optimise Early-Stage Cancer Screening (2019)
Conference Proceeding
Figueredo, G. P., Shi, P., Parkes, A. J., Evans, K., Garibaldi, J. M., Negm, O., …Robertson, J. (2019). A Hybrid Evolutionary Strategy to Optimise Early-Stage Cancer Screening. In 2019 IEEE Congress on Evolutionary Computation (CEC) (95-102). https://doi.org/10.1109/CEC.2019.8790316

Current methods to identify cutoff values for tumour-associated molecules (antigens) discrimination are based on statistics and brute force. These methods applied to cancer screening problems are very inefficient, especially with large data sets with... Read More about A Hybrid Evolutionary Strategy to Optimise Early-Stage Cancer Screening.

A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer (2019)
Journal Article
Robertson, J. F. R., Jiang, Z., Di Leo, A., Ohno, S., Pritchard, K. I., Ellis, M., …Campbell, C. (2019). A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer. Breast Cancer, 26(6), 703-711. https://doi.org/10.1007/s12282-019-00973-4

Background Fulvestrant, a selective estrogen receptor degrader, is approved for first- and second-line treatment of postmenopausal women with hormone receptor-positive advanced breast cancer (ABC). Methods Meta-analysis of randomized controlled... Read More about A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer.